NCT07218354View on ClinicalTrials.gov

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

438

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

January 26, 2029

Conditions

Alcohol Use Disorder

Interventions

DRUG

Semaglutide

Weekly subcutaneous injections of semaglutide up to 2.4 mg/week or maximum tolerated dose. Initial dosing starting at 0.25 for weeks 1-4. Further titration up to 2.4 mg weekly starting at week 5.

DRUG

Placebo

Weekly subcutaneous injections of placebo.

Trial Locations (1)

19104-4551

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia

All Listed Sponsors

lead

VA Office of Research and Development

FED